Comment
Author: Admin | 2025-04-28
The topic of female sexual dysfunction has been brought front and center due to a recently published NY Times article discussing the ongoing clinical trials of Lybrido and Lybridos, two drugs currently being studied in women reporting chronically low libido. The studies are being conducted by the clinical research center Emotional Brain in both the Netherlands and the U.S. Lybrido is being developed for women with hypoactive sexual desire disorder (HSDD) with a relatively insensitive system for sexual cues, while Lybridos is being investigated in women with HSDD and maladaptive sexual inhibitory mechanisms. Both drugs help to increase libido about 3 to 6 hours after intake. Lybrido combines testosterone with sildenafil, a PDE5 inhibitor that produces smooth muscle relaxation and allows for blood flow into the organs of arousal. Sildenafil is the active ingredient of Pfizer‘s Viagra, a product approved for treating erectile dysfunction. Lybridos combines testosterone with buspirone, an anti-anxiety medication. Buspirone acts on serotonin (5-HT1A) receptors, suppressing the release of serotonin into the bloodstream. An increase in serotonin levels, known to cause a decrease in sex drive, results in a declined release of the neurotransmitter associated with feelings of desire, dopamine, from the medial preoptic and ventral tegmental areas, says Jim Pfaus, PhD, professor of psychology and neuroscience at Concordia University in Montreal. Though the mechanism of action is not fully elucidated, the testosterone component of these drugs promotes the production and release of dopamine. While some may see the development of a low libido therapy as a
Add Comment